{"id":"background-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Background Therapy does not refer to a single pharmaceutical agent but rather to the existing or standard treatment that patients receive as part of a clinical trial protocol. It serves as the comparator or foundation upon which investigational therapies are added or compared. The specific mechanism depends entirely on what drugs comprise the background regimen.","oneSentence":"Background Therapy is a general term referring to the standard or baseline treatment regimen used as a control or foundation in clinical studies, rather than a specific drug with a defined mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:28:16.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07218029","phase":"PHASE3","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":815},{"nctId":"NCT06963827","phase":"PHASE3","title":"A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-15","conditions":"Kidney Disease","enrollment":347},{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT07398859","phase":"PHASE2","title":"Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03-19","conditions":"Seasonal Allergic Rhinitis","enrollment":300},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07201129","phase":"PHASE3","title":"A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2026-02-09","conditions":"Nephritis, Lupus, Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06339008","phase":"PHASE3","title":"A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-26","conditions":"Perennial Allergic Rhinitis (PAR)","enrollment":450},{"nctId":"NCT04905082","phase":"NA","title":"HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-12-30","conditions":"Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma","enrollment":465},{"nctId":"NCT06338995","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-29","conditions":"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","enrollment":510},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT06989437","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":982},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT07479095","phase":"NA","title":"Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2025-07-03","conditions":"Lepidic-Predominant Lung Adenocarcinoma, Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT05352919","phase":"PHASE3","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Biogen","startDate":"2022-06-10","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":864},{"nctId":"NCT07356830","phase":"NA","title":"Nurse-Led Staged Art Therapy Effects on Psychological Distress and Pregnancy Outcomes in AIH: RCT","status":"ENROLLING_BY_INVITATION","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2025-08-06","conditions":"Music Therapy","enrollment":254},{"nctId":"NCT07460336","phase":"NA","title":"Effects of Cofrogliptin on Beta-Cell Function in LADA Patients","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-15","conditions":"Latent Autoimmune Diabetes in Adults (LADA)","enrollment":84},{"nctId":"NCT06554301","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-10-20","conditions":"Pulmonary Arterial Hypertension","enrollment":72},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT05811338","phase":"NA","title":"Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-07-31","conditions":"Mild Cognitive Impairment","enrollment":312},{"nctId":"NCT04165746","phase":"NA","title":"Early Institutionalization Intervention Impact Project","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-03-16","conditions":"Socioemotional Development, Cognitive Ability, Behavioral and Neural Patterns of Attention","enrollment":220},{"nctId":"NCT07478575","phase":"","title":"Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2019-01-01","conditions":"Heart Failure, Anemia, Renal Insufficiency","enrollment":85},{"nctId":"NCT05389449","phase":"PHASE3","title":"A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-10-28","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT05663866","phase":"PHASE2","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":68},{"nctId":"NCT05081999","phase":"PHASE4","title":"De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2023-01-30","conditions":"Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy","enrollment":59},{"nctId":"NCT07452016","phase":"NA","title":"AI-guided Prediction and Treatment of Cardiac Arrest","status":"NOT_YET_RECRUITING","sponsor":"MetroHealth Medical Center","startDate":"2026-08","conditions":"Sudden Cardiac Arrest","enrollment":68},{"nctId":"NCT05851443","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-11","conditions":"Moderate to Severe Asthma","enrollment":240},{"nctId":"NCT07475650","phase":"NA","title":"Virtual Reality in ICU Patients With COPD","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2022-11-29","conditions":"COPD, Sleep Quality of ICU Patients, Anxiety","enrollment":50},{"nctId":"NCT06741969","phase":"PHASE3","title":"Nipocalimab in Moderate to Severe Sjogren's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-04","conditions":"Sjogrens Syndrome","enrollment":655},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT07438496","phase":"PHASE3","title":"A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-03-05","conditions":"Lupus Erythematosus, Systemic","enrollment":600},{"nctId":"NCT06559306","phase":"PHASE3","title":"Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-07-25","conditions":"Depressive Disorder, Major","enrollment":752},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT06813911","phase":"PHASE3","title":"Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-30","conditions":"Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":340},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT07466017","phase":"PHASE2","title":"A Study of CS060380 Tablets in Patients With MASH and Obesity","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-04-14","conditions":"Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT04432116","phase":"NA","title":"Time and Virtual Reality in Schizophrenia and Bipolar Disorder","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2021-08-12","conditions":"Schizophrenia, Bipolar Disorder","enrollment":120},{"nctId":"NCT03626688","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2018-08-30","conditions":"PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":687},{"nctId":"NCT07256392","phase":"PHASE3","title":"Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria","status":"RECRUITING","sponsor":"Celldex Therapeutics","startDate":"2025-11-25","conditions":"Chronic Spontaneous Urticaria","enrollment":1370},{"nctId":"NCT06308978","phase":"PHASE1","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-03-28","conditions":"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)","enrollment":244},{"nctId":"NCT07459452","phase":"PHASE2","title":"Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-04","conditions":"Perennial Allergic Rhinitis","enrollment":135},{"nctId":"NCT07266090","phase":"PHASE2","title":"A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)","status":"ENROLLING_BY_INVITATION","sponsor":"Viatris Pharmaceuticals Co., Ltd.","startDate":"2026-01-14","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":15},{"nctId":"NCT02354014","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-03","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":60},{"nctId":"NCT05982938","phase":"","title":"Danicopan Early Access Program","status":"AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis","enrollment":""},{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT06139796","phase":"PHASE1, PHASE2","title":"Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV","status":"WITHDRAWN","sponsor":"PENTA Foundation","startDate":"2025-02-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT04648280","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-06-30","conditions":"HIV Infections With Multi Drug Resistant Virus","enrollment":60},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":"Prostatic Neoplasms","enrollment":10},{"nctId":"NCT04028570","phase":"NA","title":"A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-09-05","conditions":"Mesothelioma; Lung","enrollment":15},{"nctId":"NCT06628622","phase":"PHASE1","title":"A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-01-27","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07157787","phase":"PHASE2","title":"Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-09-19","conditions":"Primary Membranous Nephropathy","enrollment":30},{"nctId":"NCT05672576","phase":"PHASE3","title":"A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2023-06-26","conditions":"Lupus Erythematosus, Systemic","enrollment":451},{"nctId":"NCT05818137","phase":"PHASE3","title":"A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-10","conditions":"Pulmonary Arterial Hypertension","enrollment":46},{"nctId":"NCT05648500","phase":"PHASE3","title":"A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Viatris Innovation GmbH","startDate":"2022-12-13","conditions":"Lupus Erythematosus, Systemic","enrollment":420},{"nctId":"NCT06475742","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus","status":"ENROLLING_BY_INVITATION","sponsor":"Viatris Innovation GmbH","startDate":"2024-07-30","conditions":"Lupus Erythematosus, Systemic","enrollment":680},{"nctId":"NCT07108153","phase":"PHASE2","title":"Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta","status":"RECRUITING","sponsor":"Sionna Therapeutics Inc.","startDate":"2025-11-03","conditions":"Cystic Fibrosis (CF)","enrollment":16},{"nctId":"NCT04896008","phase":"PHASE3","title":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":173},{"nctId":"NCT07438106","phase":"PHASE2","title":"A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02","conditions":"Locally Advanced Pancreatic Cancer With KRAS G12D Mutation","enrollment":30},{"nctId":"NCT06071858","phase":"NA","title":"Enhanced Coordinated Specialty Care for Early Psychosis","status":"RECRUITING","sponsor":"Mclean Hospital","startDate":"2024-02-01","conditions":"Psychosis, Schizophrenia, Schizoaffective Disorder","enrollment":350},{"nctId":"NCT05835310","phase":"PHASE3","title":"An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-14","conditions":"Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07426705","phase":"PHASE4","title":"Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","startDate":"2026-02-15","conditions":"Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS","enrollment":100},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT01649765","phase":"PHASE2","title":"Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-07","conditions":"Systemic Lupus Erythematosus","enrollment":93},{"nctId":"NCT06324864","phase":"NA","title":"START NOW Adapted: Culturally Adapted Version of START NOW","status":"RECRUITING","sponsor":"Prof. Christina Stadler","startDate":"2024-03-13","conditions":"Depression, Depression/Anxiety, Anxiety","enrollment":80},{"nctId":"NCT05295459","phase":"PHASE3","title":"Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)","status":"COMPLETED","sponsor":"Lyra Therapeutics","startDate":"2022-05-13","conditions":"Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)","enrollment":182},{"nctId":"NCT07421284","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2026-03-31","conditions":"Non-familial Hypercholesterolemia and Mixed Hyperlipidemia","enrollment":900},{"nctId":"NCT06702189","phase":"NA","title":"The Effects of EXOPULSE Mollii Suit on Low Back Pain","status":"RECRUITING","sponsor":"Institut De La Colonne Vertebrale Et Des Neurosciences","startDate":"2024-05-07","conditions":"Low Back Pain","enrollment":30},{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT07406126","phase":"","title":"Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Fernando Gómez Muñoz","startDate":"2026-02","conditions":"Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases","enrollment":30},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":"Obesity, Overweight, Overweight With One Weight Related Comorbidity","enrollment":285},{"nctId":"NCT07130955","phase":"NA","title":"A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Golden Leaf MedTec Co. Ltd","startDate":"2025-08-08","conditions":"Hypertension, CKD - Chronic Kidney Disease","enrollment":236},{"nctId":"NCT05013788","phase":"NA","title":"Using Social Media to Decrease Healthcare Utilization for Pediatric Asthma","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-10-01","conditions":"Asthma in Children","enrollment":200},{"nctId":"NCT07370636","phase":"NA","title":"Binaural Beats Stimulation on the Autonomic Nervous System (ANS), Kinesiophobia and Fitness Levels in Professional Athletes With Musculoskeletal (MSK) Injuries","status":"NOT_YET_RECRUITING","sponsor":"University of West Attica","startDate":"2026-02","conditions":"Kinesiophobia (Fear of Movement), Musculoskeletal Injuries","enrollment":66},{"nctId":"NCT04895241","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-05-25","conditions":"Lupus Erythematosus, Systemic","enrollment":548},{"nctId":"NCT04539964","phase":"PHASE3","title":"Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"SetPoint Medical Corporation","startDate":"2021-01-11","conditions":"Rheumatoid Arthritis","enrollment":243},{"nctId":"NCT07052097","phase":"PHASE2","title":"Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-31","conditions":"Seasonal Allergic Rhinitis","enrollment":136},{"nctId":"NCT07231289","phase":"NA","title":"Effect of Soundscapes on Emotional Distress in Fibromyalgia: a 4×4 Crossover Trial","status":"COMPLETED","sponsor":"Universidad de Granada","startDate":"2025-11-24","conditions":"Fibromyalgia Syndrome","enrollment":72},{"nctId":"NCT07393438","phase":"PHASE2","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-02-21","conditions":"Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB","enrollment":120},{"nctId":"NCT06863545","phase":"NA","title":"Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-22","conditions":"Coronary Artery Disease, CT Angiography, PCSK9","enrollment":3596},{"nctId":"NCT07391722","phase":"PHASE2","title":"DNV001 Injection in Patients With Hypercholesterolemia","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Dinovate Biotech Co., Ltd","startDate":"2026-02-05","conditions":"Primary Hypercholesterolemia","enrollment":120},{"nctId":"NCT07389824","phase":"NA","title":"Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.","status":"NOT_YET_RECRUITING","sponsor":"Qin Yu","startDate":"2026-02-01","conditions":"Ulcerative Colitis","enrollment":80},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":"Septic Shock, Vasodilatory Shock","enrollment":40},{"nctId":"NCT07385950","phase":"","title":"Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2026-01-15","conditions":"PET / CT, Solid Tumors, Adult","enrollment":100},{"nctId":"NCT06072482","phase":"PHASE4","title":"A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-02-07","conditions":"Antineutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":300},{"nctId":"NCT05306353","phase":"PHASE2","title":"CD40L Antagonism in Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-07-25","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT04961567","phase":"PHASE3","title":"A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2021-07-16","conditions":"Lupus Erythematosus, Systemic","enrollment":562},{"nctId":"NCT05174221","phase":"PHASE1","title":"A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-11-09","conditions":"Kidney Disease, Glomerulonephritis","enrollment":17},{"nctId":"NCT05156320","phase":"PHASE3","title":"Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam","status":"COMPLETED","sponsor":"Scholar Rock, Inc.","startDate":"2022-04-14","conditions":"Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2","enrollment":188},{"nctId":"NCT05455606","phase":"NA","title":"Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-10-14","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":1284},{"nctId":"NCT04564339","phase":"PHASE2","title":"Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-01-19","conditions":"Lupus Nephritis, Immunoglobulin A Nephropathy","enrollment":123},{"nctId":"NCT07355361","phase":"PHASE2","title":"Huaier Granule and Proteinuria","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-15","conditions":"Proteinuria, Breast Cancer Patients","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":983,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Background Therapy","genericName":"Background Therapy","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}